Vera Therapeutics TRUTAKNA Shows Two-Year Kidney Benefit
Brisbane, California, USA, September 15, 2026 Vera Therapeutics has announced final efficacy results from the Phase 3 ORIGIN 3...
IgAN
Advertisement
Alebund’s AP308 Gets FDA IND Clearance for IgA Nephropathy
Shanghai, China, September 8, 2026 Alebund Pharmaceuticals has announced that the U.S. Food and Drug Administration (FDA) has cleared...
Climb Bio Phase 1 Data Support CLYM116 Q12W Dosing in IgA Nephropathy
Wellesley Hills, Mass., September 3, 2026 Climb Bio announced positive initial Phase 1 clinical data for CLYM116, its investigational...
Boulevard Bio Launches with $65M to Advance Immunology
NEW YORK, New York, August 12, 2026 Boulevard Bio has emerged from stealth with approximately $65 million in financing...
Otsuka Advances VOYXACT with Landmark Two-Year Phase 3 IgAN Results
TOKYO, Japan, August 4, 2026 Otsuka Pharmaceutical Co., Ltd. and Otsuka Pharmaceutical Development & Commercialization, Inc. announced new two-year...
Advertisements
Novartis Fabhalta Wins Full FDA Approval for IgAN
BASEL, July 17, 2026 Novartis announced that the U.S. Food and Drug Administration (FDA) has granted traditional approval for...
Otsuka Advances VOYXACT Toward Traditional FDA Approval with Phase 3 Success
PRINCETON, N.J. and TOKYO, Japan, July 1, 2026 Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd....
Alexion’s Ultomiris Gets FDA Priority Review for IgAN
BOSTON, US | June 15, 2026 Alexion, AstraZeneca Rare Disease announced that the U.S. Food and Drug Administration (FDA)...
AstraZeneca’s Ultomiris Shows Strong IgAN Phase III Results
GLASGOW, Scotland – June 6, 2026 AstraZeneca’s rare disease division, Alexion, has reported positive interim Phase III results for...
Climb Bio Advances CLYM116 After Encouraging Phase 1 Safety Results
WELLESLEY HILLS, Mass., June 5, 2026 Climb Bio, Inc. announced the presentation of initial Phase 1 safety data and...
Advertisement
